Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma.
Immune-related adverse events
Malignant pleural mesothelioma
Nivolumab
Therapeutic effect
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
15 Nov 2021
15 Nov 2021
Historique:
received:
13
09
2021
accepted:
11
11
2021
entrez:
16
11
2021
pubmed:
17
11
2021
medline:
8
2
2022
Statut:
epublish
Résumé
Nivolumab is used for the treatment of malignant pleural mesothelioma (MPM). However, immune-related adverse events (irAEs) occur in patients treated with nivolumab. Several studies have reported the correlation between irAEs and therapeutic effects of immune checkpoint inhibitor, but none have reported the correlation in MPM. Here we report a retrospective study which shows the correlation between irAEs and therapeutic effects of nivolumab in patients with MPM. This study included patients treated with nivolumab at Tokushima University Hospital from February 2009 to September 2021. We retrospectively reviewed the medical records to evaluate the several clinical factors, such as the presence or absence of irAEs, their severities, progression-free survival (PFS), overall survival (OS) or objective response to the treatment. Eleven patients received treatment with nivolumab. Objective response rate was 18.2% and the disease control rate was 90.9%. Median PFS was 6.8 months (95% confidence interval, 1.3 to 11.9 months) and median OS was 15.2 months (95% confidence interval, 8.9 to 21.5 months). IrAEs occurred in eight patients (72.7%), and grade ≥ 2 irAEs occurred in six patients (54.5%). PFS and OS were significantly longer in the grade ≥ 2 irAEs group than in grade < 2 irAEs group (median PFS 13.6 vs. 3.8 months, p = 0.0093; median OS not reached vs. 8.6 months, p = 0.0108). This is the first study to report the correlation between irAEs and therapeutic effects in patients with MPM. Because the presence of irAEs may be associated with a favorable clinical outcome, early detection and appropriate management of irAEs will increase the therapeutic benefits to patients.
Sections du résumé
BACKGROUND
BACKGROUND
Nivolumab is used for the treatment of malignant pleural mesothelioma (MPM). However, immune-related adverse events (irAEs) occur in patients treated with nivolumab. Several studies have reported the correlation between irAEs and therapeutic effects of immune checkpoint inhibitor, but none have reported the correlation in MPM. Here we report a retrospective study which shows the correlation between irAEs and therapeutic effects of nivolumab in patients with MPM.
METHODS
METHODS
This study included patients treated with nivolumab at Tokushima University Hospital from February 2009 to September 2021. We retrospectively reviewed the medical records to evaluate the several clinical factors, such as the presence or absence of irAEs, their severities, progression-free survival (PFS), overall survival (OS) or objective response to the treatment.
RESULTS
RESULTS
Eleven patients received treatment with nivolumab. Objective response rate was 18.2% and the disease control rate was 90.9%. Median PFS was 6.8 months (95% confidence interval, 1.3 to 11.9 months) and median OS was 15.2 months (95% confidence interval, 8.9 to 21.5 months). IrAEs occurred in eight patients (72.7%), and grade ≥ 2 irAEs occurred in six patients (54.5%). PFS and OS were significantly longer in the grade ≥ 2 irAEs group than in grade < 2 irAEs group (median PFS 13.6 vs. 3.8 months, p = 0.0093; median OS not reached vs. 8.6 months, p = 0.0108).
CONCLUSIONS
CONCLUSIONS
This is the first study to report the correlation between irAEs and therapeutic effects in patients with MPM. Because the presence of irAEs may be associated with a favorable clinical outcome, early detection and appropriate management of irAEs will increase the therapeutic benefits to patients.
Identifiants
pubmed: 34781910
doi: 10.1186/s12890-021-01746-6
pii: 10.1186/s12890-021-01746-6
pmc: PMC8591924
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Nivolumab
31YO63LBSN
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
373Informations de copyright
© 2021. The Author(s).
Références
JAMA Oncol. 2016 Oct 1;2(10):1346-1353
pubmed: 27367787
J Surg Oncol. 2001 Nov;78(3):171-4
pubmed: 11745800
JCO Precis Oncol. 2017;2017:
pubmed: 29850653
BMC Cancer. 2020 Jul 14;20(1):656
pubmed: 32664888
JAMA Oncol. 2020 Jun 1;6(6):865-871
pubmed: 32297899
J Clin Oncol. 2020 Jan 1;38(1):11-19
pubmed: 31725351
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
Clin Cancer Res. 2016 Feb 15;22(4):886-94
pubmed: 26446948
Clin Cancer Res. 2019 Sep 15;25(18):5485-5492
pubmed: 31164373
J Thorac Oncol. 2018 Oct;13(10):1569-1576
pubmed: 29908324
J Clin Oncol. 2015 Mar 1;33(7):773-81
pubmed: 25605840
J Thorac Oncol. 2017 May;12(5):850-859
pubmed: 28257959
Ann Oncol. 2004 Feb;15(2):257-60
pubmed: 14760119
JAMA Oncol. 2018 Mar 1;4(3):374-378
pubmed: 28975219
J Clin Oncol. 2003 Jul 15;21(14):2636-44
pubmed: 12860938
N Engl J Med. 2020 Oct 1;383(14):1328-1339
pubmed: 32997907
J Dermatol. 2017 Feb;44(2):117-122
pubmed: 27510892
CA Cancer J Clin. 2019 Sep;69(5):402-429
pubmed: 31283845
Chest. 1995 Jun;107(6 Suppl):332S-344S
pubmed: 7781415
J Clin Oncol. 1996 Mar;14(3):1007-17
pubmed: 8622005
In Vivo. 2021 Jan-Feb;35(1):475-482
pubmed: 33402499